Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

US FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell disease: Paris Thursday, June 5, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ( ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in ...

Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

A key phase 3 readout in immune thrombocytopenia is due later this year, along with phase 2 results in asthma, IgG4-related disease, and warm autoimmune haemolytic anaemia, and phase 3 testing in ...

Zenas BioPharma has released its corporate presentation for June 2025, providing an insight into its financial and clinical ...

The FDA has granted orphan drug status to rilzabrutinib, an investigational therapy to prevent pain crises in sickle cell ...

tmu.edu.cn Objectives The aim of this study is to profile the transcriptional landscapes of affected tissues and peripheral blood mononuclear cells (PBMCs) at the single-cell level in IgG4-related ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...